Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: A mass balance study

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2855-2861

  McDowell, James A ^a   Chittick, Gregory E ^a   Ravitch, Joshua R ^a   Polk, Ronald E ^b   Kerkering, Thomas M ^b   Stein, Daniel S ^a  

^a GLAXOSMITHKLINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG URINE LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; CEREBROSPINAL FLUID; CHEMISTRY; DRUG ANTAGONISM; FECES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; ULTRAVIOLET SPECTROPHOTOMETRY;

ADULT; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIDEOXYNUCLEOSIDES; FECES; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0032585875     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2855     Document Type: Article

References (24)

1. Adkins, J. C., D. H. Peters, and D. Faulds. 1997. Zalcitabine: an update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 53:1054-1080.
2. Beach, J. W. 1998. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther. 20:2-25.
3. Bulkowski, D., and W. Wargin. 1994. Protein binding of 1592U89 in human, monkey, and mouse plasma (PDM043). Document TBZZ/93/0010, 22 February, Glaxo Wellcome, Inc., Research Triangle Park, N.C.
4. Burger, D. M., C. L. Kraaijeveld, P. L. Meenhorst, J. W. Mulder, C. H. W. Koks, A. Bult, and J. H. Beijnen. 1993. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 7:1581-1587.
5. Centers for Disease Control and Prevention. 1992. 1993 revised classification system for HIV infection and expanded case surveillance definition in adolescents and adults. Morbid. Mortal, Weekly Rep. 41(51):961-962.
6. Chittick, G. E., C. Gillotin, J. A. McDowell, Y. Lou, K. D. Edwards, W. T. Prince, and D. S. Stein. Abacavir (1592U89): absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 19:932-942.
7. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. M. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
8. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective, anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
9. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Amimicrob. Agents Chemother. 41: 1099-1107.
10. Faulds, D., and R. N. Brogden. 1992. Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44:94-116.
11. Feinberg, M. B., C. Carpenter, A. S. Fauci, S. K. Stanley, O. Cohen, J. G. Bartlett, J. E. Kaplan, and E. Abrutyn. 1998. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann. Intern. Med. 128:1057-1100.
12. Good, S. S., S. M. Daluge, S. V. Ching, M. M. Ayers, W. B. Mahony, M. B. Falletto, B. A. Domin, B. S. Owens, R. E. Dornsife, J. A. McDowell, S. W. LaFon, and W. T. Symonds. 1995. 1592U89 succinate-preclinical toxicological and disposition studies and preliminary clinical pharmacokinetics. Antivir. Res. 26:A229.
13. Good, S. S., B. X. Owens, M. B. Faletto, W. B. Mahony, and B. A. Domin. 1994. Disposition in monkeys and mice of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, a potent inhibitor of HIV, abstr. 186, p. 92. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Kumar, P. N., D. E. Sweet, J. A. McDowell, W. Symonds, Y. Lou, S. Hetheringtoo, and S. LaFon. 1999. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 43:603-608.
15. Nau, R., G. Zysk, A. Thiel, and H. W. Prange. 1993. Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man. Eur. J. Clin. Pharmacol. 45:469-475.
16. Perry, C. M., and D. Faulds. 1997. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 53:657-680.
17. Portegies, P., and N. R. Rosenberg. 1998. AIDS dementia complex: diagnosis and drug treatment options. CNS Drugs 9:31-40.
18. Rana, K. Z., and M. N. Dudley. 1997. Clinical pharmacokinetics of stavudine. Clin. Pharmacokinet. 33:276-284.
19. Ravitch, J. R., B. J. Bryant, M. J. Reese, C. C. Boehlert, J. S. Walsh, J. P. McDowell, and B. M. Sadler. 1998. In vivo and in vitro studies of the potential for drug interactions involving the antiretroviral 1592 in humans, abstr. 634, p. 199. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Chicago, Ill.
20. Ravitch, J. R., J. L. Jarrett, W. H. Robertson, J. W. Polli, J. E. Humphreys, and S. S. Good. 1998. CNS penetration of the anti-retroviral 1592 in human and animal models, abstr. 636, p. 199. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Chicago, Ill.
21. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1093-1098.
22. Wang, L. H., G. E. Chittick, and J. A. McDowell. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with HIV infection. Antimicrob. Agents Chemother. 43:1708-1715.
23. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
24. Yarchoan, R., H. Mitsuya, C. E. Myers, and S. Broder. 1989. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321:726-738.